ABOUT US
Mission and Objectives
Message from the Chairman
Message from the Secretary General
Who Are We?
Board of Directors
Our Members
Inspection Board
Committees
Pharmacovigilance Committee
Intellectual Property Rights Committee
GCP Committee
Reimbursement Committee
GPP Committee
OTC (Non-Prescription Drugs) Committee
PR Committee
Regulatory Affairs Committee
Anti-Counterfeiting Committee
Charter
Name of the Association
Head Office
Mission and Activities of the Association
Membership
Terms of Joining and Terminating
Bodies of the Association
General Assembly
Board of Directors
Inspection Board
Internal Audit
Secretary General
Acquisition of Property
Revenues and Expenditures of the Assoc.
Dissolution of the Association
Records of the Association
Charter Amendments
Absence of Ruling
Applicable Language
Founders of the Association
Temporary Article
Code of Promotion
Position Documents
SECTORIAL DATA
Announcements of Moh & Legislation
Frequently Asked Questions
NEW DRUGS AND R&D
What does it mean to be researcher?
What is an “Original” drug?
Implementations (Original & Generic)
Patent Protection
Data Exclusivity
PRESS ROOM
Press Announcement
Press Releases
News
Insider AİFD
Activities
Reflections in the Press
RESEARCHES AND PUBLICATIONS
AIFD ACADEMY
About AİFD Academy
AİFD Academy Final Declaration
Scientific Advisory Board
AİFD Academy E-Bulletin Membership
TR
EN
AGENDA
Association of Research-Based Pharmaceutical Companies (AİFD)
18.09.2009
NEWS
UNCERTAINTIES WITH THE DRUG TRACKING SYSTEM PUT PATIENTS, SECTOR IN A BIND
18.02.2010
BIOTECHNOLOGY LEADER GENZYME JOINS AIFD
02.02.2010
AİFD PRESS RELEASE
18.01.2010
New pricing decree to shrink pharma industry by 25%
10.12.2009
Pharma compromise reached
03.12.2009
33.4 Million With HIV Still Alive Thanks to Innovative Drugs and Therapies
30.11.2009
Difficulties Expected, Stemming From New Price Decree
20.11.2009
Armed with Innovative Vaccines, World Fights Swine Flu
12.11.2009
On Patient Rights Day, Patient’s Access To Drugs At Stake
26.10.2009
New Pharma Investments At Stake
12.10.2009
New Pricing Decree To Distress Pharma Industry
01.10.2009
Patient Health May Be At Risk
19.09.2009
Effective Struggle Against Cancer Requires New Drugs and Treatments
16.09.2009
AİFD Welcomes IBSA
08.09.2009
Aifd: "Restricting Tobacco Use Will Make Turkey Healthier"
17.07.2009
AİFD: Close Collaboration And Harsh Penalties Key To Combating Counterfeit Drugs
01.07.2009
According To OECD Innovation Is Key To Emerging From The Current Crisis
24.06.2009
Cancer- Related Death Rates Decrease In Developed Countries
18.06.2009
Turkey’s Competitive Power Results To Be Weak In Innovative Drug Researches
09.06.2009
Muhittin Bilgütay is reelected AIFD Chairperson
03.06.2009
Alp Sevindik, AİFD Secretary General and the Chief Operating Officer
13.05.2009
Eczacıbaşı – Baxter Has Become A Member Of Aifd
03.04.2009
Japanese pharmaceutical giant in Turkey - 38th Member of Aifd is Astellas
31.03.2009
Updated version of the “AİFD Code of Good Promotional Practice” has become effective.
03.09.2008
AİFD Convened its Sixth Ordinary General Assembly
27.05.2008
AİFD: “If adequate conditions are provided, brain-drain can be reversed”
15.04.2008
New R&D Law Will Enhance Investments
26.02.2008
FDA’s Former Associate Commissioner for External Relations, Pitts:"SAFE DRUGS SHOULD BE PRESENTED TO PATIENTS MORE EXPEDITIOUSLY"
11.07.2007
This Years’ Final Activity of the Patient School will take place at the School of Medicine of İstanbul University
19.06.2007
All News »
SEARCH IN SITE
INNOVATIVE DRUGS AND R&D
What does it mean to be a researcher?
Being able to offer resources, technology and working environment for years of research by tens of thousands of scientists even if a molecule’s probability of becoming a benef...
More >>
MESSAGE FROM THE SECRETARY
Turkey is experiencing a crescendo of social and economic developments at breath taking speed like a movie. Not long ago, our discussions were
more »
MESSAGE FROM THE CHAIRMAN
Turkey needs a robust pharma industry
The Turkish pharmaceutical sector is going through a period of unprecedented challenges and hardship....
more »
MESSAGE FROM THE SECRETARY
How did we come to this point?
Turkey is experiencing a crescendo of social and economic developments at breath taking speed like a movie. Not long ago, our discussions were...
more »
ACTIVITIES
1st International Congress on Epilepsy,...
17 March Wednesday,
PRAG
FREQUENTLY ASKED QUESTIONS
How does data protection encourage developing new drugs?
What are AİFD’s efforts on ethical promotion practices?
MEMBER LOGIN
INSIDER AİFD
Our pharmaceutical industry, global competition and opportunities
DID YOU KNOW THAT…?
IMPORTANT TERMS
SITE MAP
USEFUL LINKS
CONFIDENTIALITY-TERMS OF USE
CONTACT
Abbott
•
Actelion
•
Alcon
•
Amgen
•
Astellas
•
AstraZeneca
•
Bayer Türk Kimya San. Ltd. Şti.
•
Boehringer İngelheim
•
Bristol-Myers Squibb
•
Celgene
•
Chiesi
•
Daiichi-Sankyo
•
Eczacıbaşı-Baxter
•
Ferring
•
Fresenius Kabi
•
Fresenius Medical Care
•
Genzyme Sağlık Hizmetleri ve Tedavi Ürünleri Tic.Ltd.Şti.
•
Gilead Sciences İlaç.Tic. Ltd. Şti.
•
GlaxoSmithKline
•
IBSA İlaç San. ve Tic. Ltd. Şti.
•
Intendis
•
İ.E.Ulagay
•
Johnson&Johnson
•
Lilly
•
Lundbeck
•
Merck Serono
•
MSD Türkiye
•
Nestle
•
Novartis Sağlık Ürünleri
•
Novo Nordisk
•
Nutricia Klinik Beslenme
•
Pfizer İlaçları Ltd. Şti
•
PharmaSwiss
•
Pierre Fabre
•
Sanofi-aventis
•
Schering-Plough
•
Servier
•
Solvay İlaç Türkiye
•
U.C.B. Pharma
•
Wyeth
•
© Association of Research-Based Pharmaceutical Companies
Last Update :
10.03.2010